Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2001

View Archived Issues

Novel chimeric protein with potential application as HIV therapy available for licensing from NIH

Licensing opportunity from NIH: beta2-microglobulin fusion proteins

Bayer and m-phasys collaborate on protein-targeting drug discovery tools

Preclinical pipeline at Faes includes new antidepressant and antipsychotic agents

Nerve injury-induced gene discovered by Washington University scientists

GlaxoSmithKline and Taisho collaborate on smoking control products

Antisoma enters supply agreement for thioplatin

Genentech highlights business and product events for Q2 2001

Liposome-mediated eNOS gene transfection for reducing myocardial ischemia-reperfusion injury

New England Journal of Medicine publishes pivotal data for Fabrazyme

Aventis licenses new solid tumor treatment from Ajinomoto

Significant clinical antileukemic activity demonstrated for signal transduction inhibitor

Antigenics finalizes acquisition of Aronex; broadens pipeline

Alpha1A-adrenoceptor blockade not associated with improvement in MED

Vion awarded SBIR grant to support development of sulfonyl hydrazine prodrugs

Vevesca enters U.S. trial for Gaucher's disease

Mozenavir vs. indinavir in antiretroviral-naive HIV patients

Pharmacia receives nonapprovable letter from FDA for analgesic product

Dynamics of anti-HIV response to GPG-NH2 examined after oral and s.c. dosing

Consensus granted NIH funding to support research on HIV entry inhibitors

Immunex advances IL-1 regulator to clinical trials

MedImmune evaluates Vitaxin in new clinical trial in colorectal cancer patients

Treatment of mild cognitive impairment with glucocorticoid receptor antagonists

Australian researchers identify new tumor suppressor gene

HIV protease inhibitors designed at Merck with improved activity against HIV mutants

Preparation and use of CSBP/p38 kinase inhibitors in respiratory and other inflammatory disorders

Sepracor preparing for NDA submission of insomnia drug candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal
BioWorld
Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui...
Unique trial strategy muddies the ODAC waters for camizestrant
BioWorld
Following a discussion that focused more on a new personalized trial strategy rather than the proposed therapy, the U.S. FDA’s Oncologic Drugs Advisory Committee...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...